Search / Trial NCT00000425

Toward Better Outcomes in Osteoarthritis

Launched by STANFORD UNIVERSITY · Nov 3, 1999

Trial Information

Current as of December 26, 2024

Completed

Keywords

Osteoarthritis Skeletal Disorder Chemotherapy Nonsteroidal Anti Inflammatory Drugs (Nsai Ds) Arthroplasty Cartilage Metabolism Hip Knee Outcomes Research

ClinConnect Summary

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most popular agents used to treat the joint pain and inflammation associated with OA. Although NSAIDs are useful for pain management, recent studies have not found NSAIDs to be better than acetaminophen for the treatment of painful knee OA. The relative lack of efficacy and possibility of accelerated disease progression, coupled with the known gastrointestinal risks of these medications, especially to the elderly, have led us to reevaluate NSAIDs as the first-line medical therapy for osteoarthritis. Our dominant NSAID-based approach to t...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Knee osteoarthritis
  • Moderate radiographic evidence by Kellgren and Lawrence grade 2-4
  • Knee pain \> 20 on VAS pain scale
  • Exclusion Criteria:
  • Bilateral knee replacements
  • Unwillingness to take acetaminophen for pain relief

Trial Officials

Nancy Lane, MD

Study Director

UCSF, Division of Rheumatology, SFGH

About Stanford University

Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.

Locations

San Francisco, California, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials